Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More